Travere Therapeutics, Inc. (TVTX)Healthcare | Biotechnology | San Diego, United States | NasdaqGM
56.29 USD
-0.30
(-0.530%) ⇩
(July 13, 2026, 4 p.m.
EDT)
After hours: 56.32 +0.03 (0.053%) ⇧ (July 13, 2026, 7:46 p.m. EDT) |
Hot Take ↕ | July 11, 2026, 4:12 a.m. EDT
Travere Therapeutics presents a classic biotech dilemma: exceptional top-line growth masking fragile profitability. The company is executing well, with revenue surging 55.6% year-over-year and a major drug, Filspari, finally gaining regulatory traction for a rare kidney disease. This validates the core business thesis and explains why the stock has rallied significantly from its lows. However, the balance sheet remains precarious, with debt nearly matching cash reserves and operating cash flow still negative. The market is pricing in a forward P/E of roughly 11.7, which is optimistic for a company that hasn't yet turned profitable, implying analysts believe the turnaround is imminent. The short-term outlook is cautiously bullish but fraught with uncertainty. The stock has recovered strongly from its 2024 lows, trading above its 200-day average, yet the statistical forecasting models offer almost no confidence in the immediate price direction, highlighting the noise inherent in small-cap biotech trading. The options market confirms this tension; heavy put buying at deep strikes suggests a fear of a sudden de-rating or clinical hiccup, while call interest remains focused on the near term. Given the strong revenue trajectory and the specific catalyst of Filspari approval, I am leaning slightly bullish for the next few months, betting on continued momentum as the market digests the approval news, but I am not ignoring the risk of a sharp correction if the next earnings report fails to show a path to profitability. |
| Model | MAE |
|---|---|
| AutoTheta ✓ | 0.068884 |
| AutoARIMA | 0.147498 |
| AutoETS | 0.147501 |
| MSTL | 0.164253 |
Forecast horizon: 45 days | Selected: AutoTheta
| Forecast Reliability | |
|---|---|
| Score | 28% |
| H-stat | 11.40 |
| Ljung-Box p | 0.000 |
| Jarque-Bera p | 0.032 |
| Excess Kurtosis | -0.21 |
| Attribute | Value |
|---|---|
| Sector | Healthcare |
| Debt to Equity Ratio | 331.884 |
| Revenue per Share | 5.952 |
| Market Cap | 5,234,570,752 |
| Forward P/E | 11.60 |
| Beta | 1.11 |
| Profit Margins | -4.00% |
| Previous Name | Retrophin, Inc. |
| Website | https://travere.com |
As of July 11, 2026, 4:12 a.m. EDT: Speculators are positioning for significant volatility rather than a specific directional breakout. There is a massive buildup of out-of-the-money put volume and open interest at deep strikes (22.5, 25.0, 30.0) expiring in late 2026 and early 2027, creating a 'floor' or insurance layer against a crash. Conversely, call activity is concentrated near the money (55.0-60.0) with lower implied volatilities at deep strikes, suggesting traders expect a range-bound environment or a sharp drop followed by a recovery, rather than a sustained rally to the $70 analyst target.
| Attribute | Value |
|---|---|
| 52 Week Change | 2.3465405 |
| Address1 | 3,611 Valley Centre Drive |
| Address2 | Suite 300 |
| All Time High | 60.1 |
| All Time Low | 1.5 |
| Ask | 69.95 |
| Ask Size | 2 |
| Audit Risk | 4 |
| Average Analyst Rating | 1.3 - Strong Buy |
| Average Daily Volume10 Day | 1,930,290 |
| Average Daily Volume3 Month | 2,516,514 |
| Average Volume | 2,516,514 |
| Average Volume10Days | 1,930,290 |
| Beta | 1.109 |
| Bid | 40.53 |
| Bid Size | 2 |
| Board Risk | 4 |
| Book Value | 1.068 |
| City | San Diego |
| Compensation As Of Epoch Date | 1,767,139,200 |
| Compensation Risk | 5 |
| Country | United States |
| Crypto Tradeable | 0 |
| Currency | USD |
| Current Price | 56.29 |
| Current Ratio | 3.131 |
| Custom Price Alert Confidence | HIGH |
| Date Short Interest | 1,782,777,600 |
| Day High | 56.82 |
| Day Low | 53.94 |
| Debt To Equity | 331.884 |
| Display Name | Travere Therapeutics |
| Earnings Call Timestamp End | 1,777,926,600 |
| Earnings Call Timestamp Start | 1,777,926,600 |
| Earnings Timestamp | 1,777,924,800 |
| Earnings Timestamp End | 1,777,924,800 |
| Earnings Timestamp Start | 1,777,924,800 |
| Ebitda | 16,088,000 |
| Ebitda Margins | 0.03 |
| Enterprise To Ebitda | 329.286 |
| Enterprise To Revenue | 9.88 |
| Enterprise Value | 5,297,556,480 |
| Eps Current Year | 1.86857 |
| Eps Forward | 4.8506 |
| Eps Trailing Twelve Months | -0.5 |
| Esg Populated | 0 |
| Exchange | NGM |
| Exchange Data Delayed By | 0 |
| Exchange Timezone Name | America/New_York |
| Exchange Timezone Short Name | EDT |
| Fifty Day Average | 49.1442 |
| Fifty Day Average Change | 7.1458015 |
| Fifty Day Average Change Percent | 0.14540479 |
| Fifty Two Week Change Percent | 234.65405 |
| Fifty Two Week High | 60.1 |
| Fifty Two Week High Change | -3.8099976 |
| Fifty Two Week High Change Percent | -0.0633943 |
| Fifty Two Week Low | 15.03 |
| Fifty Two Week Low Change | 41.260002 |
| Fifty Two Week Low Change Percent | 2.7451766 |
| Fifty Two Week Range | 15.03 - 60.1 |
| Financial Currency | USD |
| First Trade Date Milliseconds | 1,352,385,000,000 |
| Float Shares | 86,987,423 |
| Forward Eps | 4.8506 |
| Forward P E | 11.604751 |
| Free Cashflow | -51,166,000 |
| Full Exchange Name | NasdaqGM |
| Full Time Employees | 497 |
| Gmt Off Set Milliseconds | -14,400,000 |
| Governance Epoch Date | 1,782,864,000 |
| Gross Margins | 0.55946 |
| Gross Profits | 299,977,984 |
| Has Pre Post Market Data | 1 |
| Held Percent Insiders | 0.00796 |
| Held Percent Institutions | 1.13815 |
| Implied Shares Outstanding | 92,992,905 |
| Industry | Biotechnology |
| Industry Disp | Biotechnology |
| Industry Key | biotechnology |
| Is Earnings Date Estimate | 0 |
| Language | en-US |
| Last Fiscal Year End | 1,767,139,200 |
| Long Business Summary | Travere Therapeutics, Inc., a biopharmaceutical company, identifies, develops, and delivers therapies to people living with rare kidney and metabolic diseases in the United States. The company's products include FILSPARI (sparsentan), a once-daily, oral medication designed to target two critical pathways in the disease progression of IgA Nephropathy (endothelin 1 and angiotensin-II); and Thiola and Thiola EC (tiopronin tablets) for the treatment of cystinuria, a rare genetic cystine transport disorder that causes high cystine levels in the urine and the formation of recurring kidney stones. Its clinical-stage programs consist of Sparsentan, a novel investigational product candidate, which has been granted Orphan Drug Designation for the treatment of focal segmental glomerulosclerosis in the U.S. and Europe; and Pegtibatinase, a novel investigational human enzyme replacement candidate being evaluated for the treatment of classical homocystinuria. It has a collaboration agreement with PharmaKrysto Limited for the pre-clinical activities associated with the cystinuria program. Travere Therapeutics, Inc. was formerly known as Retrophin, Inc. and changed its name to Travere Therapeutics, Inc. in November 2020. The company is headquartered in San Diego, California. |
| Long Name | Travere Therapeutics, Inc. |
| Market | us_market |
| Market Cap | 5,234,570,752 |
| Market State | PREPRE |
| Max Age | 86,400 |
| Message Board Id | finmb_133551169 |
| Most Recent Quarter | 1,774,915,200 |
| Name Change Date | 2,026-07-13 |
| Net Income To Common | -45,637,000 |
| Next Fiscal Year End | 1,798,675,200 |
| Non Diluted Market Cap | 5,262,468,493 |
| Number Of Analyst Opinions | 14 |
| Open | 55.51 |
| Operating Cashflow | 39,612,000 |
| Operating Margins | -0.29021 |
| Overall Risk | 4 |
| Payout Ratio | 0.0 |
| Phone | 888 969 7879 |
| Post Market Change | 0.02999878 |
| Post Market Change Percent | 0.053293265 |
| Post Market Price | 56.32 |
| Post Market Time | 1,783,986,384 |
| Prev Name | Retrophin, Inc. |
| Previous Close | 56.59 |
| Price Eps Current Year | 30.124641 |
| Price Hint | 2 |
| Price To Book | 52.705994 |
| Price To Sales Trailing12 Months | 9.762439 |
| Profit Margins | -0.03995 |
| Quick Ratio | 2.816 |
| Quote Source Name | Nasdaq Real Time Price |
| Quote Type | EQUITY |
| Recommendation Key | strong_buy |
| Recommendation Mean | 1.26667 |
| Region | US |
| Regular Market Change | -0.299999 |
| Regular Market Change Percent | -0.530128 |
| Regular Market Day High | 56.82 |
| Regular Market Day Low | 53.94 |
| Regular Market Day Range | 53.94 - 56.82 |
| Regular Market Open | 55.51 |
| Regular Market Previous Close | 56.59 |
| Regular Market Price | 56.29 |
| Regular Market Time | 1,783,972,800 |
| Regular Market Volume | 1,002,865 |
| Return On Assets | -0.06461 |
| Return On Equity | -0.69383 |
| Revenue Growth | 0.556 |
| Revenue Per Share | 5.952 |
| Sand P52 Week Change | 0.20847368 |
| Sector | Healthcare |
| Sector Disp | Healthcare |
| Sector Key | healthcare |
| Share Holder Rights Risk | 4 |
| Shares Outstanding | 92,992,905 |
| Shares Percent Shares Out | 0.1364 |
| Shares Short | 12,687,615 |
| Shares Short Previous Month Date | 1,780,012,800 |
| Shares Short Prior Month | 14,122,154 |
| Short Name | Travere Therapeutics, Inc. |
| Short Percent Of Float | 0.1784 |
| Short Ratio | 5.25 |
| Source Interval | 15 |
| State | CA |
| Symbol | TVTX |
| Target High Price | 70.0 |
| Target Low Price | 43.0 |
| Target Mean Price | 58.35714 |
| Target Median Price | 59.5 |
| Total Cash | 264,676,000 |
| Total Cash Per Share | 2.846 |
| Total Debt | 327,662,016 |
| Total Revenue | 536,195,008 |
| Tradeable | 0 |
| Trailing Annual Dividend Rate | 0.0 |
| Trailing Annual Dividend Yield | 0.0 |
| Trailing Eps | -0.5 |
| Trailing Peg Ratio | None |
| Triggerable | 1 |
| Two Hundred Day Average | 36.0097 |
| Two Hundred Day Average Change | 20.2803 |
| Two Hundred Day Average Change Percent | 0.5631899 |
| Type Disp | Equity |
| Volume | 1,002,865 |
| Website | https://travere.com |
| Zip | 92,130 |